http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-030187-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d9af4d89807e0db8298692dffeabf875 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D251-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D493-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D251-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D251-18 |
| filingDate | 2013-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad196d3c5555ef028926aaad267f26d4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e111ccf0f2f49b3febe3781d76e767ae http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b8a39cb5e06d83a244c88b36f0650c43 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9adef6dea79d9ad2bb7fe2d61044f43d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba16bc1a9740dc0630cceb64644dfb04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_639416f84415831d2fffa32f62b10655 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf7a0cc86c9ad6d187c930c6caeba6a7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf7d046ec242dbddae266c5286606434 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0260883d4aa4d81fda4ff10295e198cb |
| publicationDate | 2018-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EA-030187-B1 |
| titleOfInvention | THERAPEUTICALLY ACTIVE CONNECTIONS AND METHODS OF THEIR USE |
| abstract | The invention relates to a compound of formula I or a pharmaceutically acceptable salt thereof, wherein ring A is a monocyclic heteroaryl selected from oxazolyl, isoxazolyl, pyridinyl, pyrimidinyl, pyrazinyl and thiazolyl; where ring A is optionally substituted with up to two substituents; Ring B is pyridinyl, pyrimidinyl, pyridazinyl and pyrazinyl; where ring B is optionally substituted with up to two substituents; R3 and R4 are each independently selected from hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, -OC 3-C 1-6 alkyl and CN, where any alkyl part of R 8 is optionally substituted with -OH, NH, NH (C 1-6 alkyl) or N (C 1 -C 6 alkyl) ; R is selected from - (C 1 -C 6 alkyl), - (C 1 -C 6 alkenyl or alkynyl), - (C 1 -C 6 alkylene) -N (R) - (C 1 -C 6 alkylene) -O- (C 1 -C 1-6 alkyl), - (C 1 -C 1-6 alkylene) -N (R) - (C 1 -C alkylene) -Q, - (C 1 -C 6 alkylene) -N (R) (R), etc., where any alkyl or alkylene moiety present in R is optionally substituted with one or more than —OH, —O (C 1-6 alkyl) or halogens; any terminal methyl fragment represented by R is optionally substituted with —CHOH, CF, —CHF, —CHCl, C (O) CH, C (O) CF, CN or COH; each R is independently selected from hydrogen and C 1-4 alkyl; and Q is selected from aryl, heteroaryl, C-C cycloalkyl and heterocyclyl, any of which is optionally substituted, etc., as set forth in the claims. The invention also relates to a compound of formula II or a pharmaceutically acceptable salt thereof, wherein ring A ′ is pyridin-2-yl, optionally substituted with one or two substituents independently selected from chlorine, fluorine, —CF, —CHF, —CH, —CHCH , -CFCH, -OH, -OCH, -OCHCH, -NH, -NH (CH) and -N (CH); ring B ′ is selected from pyridin-3-yl, pyridin-4-yl and pyrimidin-5-yl, where ring B ′ is optionally substituted with one or two substituents independently selected from halogen; -CN; -OH; C 1-10 alkyl optionally substituted with halogen, CN or -OH; -S (O) -C-C1-6alkyl, -S (O) -C-C1-6alkyl, -S (O) -NH -C1 C1-6alkyl, -S (O) -N (C-C1-6alkyl), -S (O) -azetidin-1-yl, -OC-C1-6alkyl, -CH-O-CH, morpholin-4-yl, cyclopropyl, -S (O) -NH-cyclopropyl, -C (O) -O-CH, etc. The invention also relates to pharmaceutical compositions based on them and the use of compounds of formula (I) for the treatment of cancer. |
| priorityDate | 2012-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 387.